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Introduction
Hidradenitis suppurativa (HS) is a debilitating chronic inflammatory skin disease characterized by chronic 
abscess formation and development of  multiple draining sinus tracts in the groin, axillae, and perineum (1). 
It has an estimated prevalence of  approximately 1% (2) and is more common in women and specific ethnic 
groups, such as African Americans (3), in which the incidence may be up to 3-fold higher than in Caucasians 
(4). It frequently arises during adolescence and is a lifelong disease with a marked negative effect on quality 
of  life (1). It is associated with several comorbidities, including obesity, and has a prominent hormonal com-
ponent (5). Several genetic mutations involving 3 gamma-secretase complex genes have been identified in 
autosomal dominant forms of  HS (6), forming the basis for the hypothesis that Notch signaling is involved in 
HS pathogenesis (7). However, these mutations account for only a small minority of  HS cases (7).
The immunopathogenesis of  HS is poorly understood, with widely and somewhat discordant patho-
genic mechanisms proposed. Complement activation has been implicated in the pathogenesis of  HS 
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and perineum. Using proteomic and transcriptomic approaches, we characterized the inflammatory 
responses in HS in depth, revealing immune responses centered on IFN-γ, IL-36, and TNF, with 
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through elevated concentration of  the complement fragment C5a in skin and blood of  patients with HS (8). 
C5a is a major chemoattractant for neutrophils, a cell population that is prominent in actively inflamed HS 
skin (9). Furthermore, increased levels of  neutrophils releasing neutrophil extracellular traps (NETs) in a 
process called NETosis have been demonstrated in both blood and skin of  patients with HS (10), along with 
increased type I IFN responses and activation of  plasmacytoid dendritic cells (pDCs) (10).
Other studies have suggested involvement of  the proinflammatory cytokines IL-17A and IFN-γ (11, 
12), as well as keratinocyte-derived IL-6 and IL-1β (11). Additional transcriptomic studies have noted the 
increased expression of  immunoglobulins and plasma cell signatures in HS (13), but a clear and comprehen-
sive view of  the immunopathogenic mechanisms involved in HS has been lacking. HS remains difficult to 
treat, with only one biologic therapy, the anti-TNF agent adalimumab, currently approved for its treatment, 
and even with adalimumab therapeutic responses are suboptimal in nearly 40% of  patients (14). Therefore, 
there is an urgent need for increasing our understanding of  this disease to facilitate therapeutic development.
In this manuscript we provide potentially novel insights into the immunopathogenesis of  HS, using 
bulk and single-cell RNA-sequencing and cytometry by time of  flight (CyTOF) imaging to outline the 
major cell types and inflammatory pathways that are dysregulated in HS skin. Our results identify immune 
complex deposition and complement activation along with B cell and plasma cell activation as critical path-
ways in HS pathogenesis and provide data suggesting that targeting plasma cell activation could provide a 
novel therapeutic approach for treating advanced HS.
Results
HS is characterized by enriched biological processes involving complement and B cell responses. Twenty-two patients 
with moderate-to-severe HS and 10 healthy controls (see Supplemental Table 1; supplemental material 
available online with this article; https://doi.org/10.1172/jci.insight.139930DS1) were enrolled, and 
lesional (HS) and matching control skin samples were obtained and submitted for bulk RNA-Seq. In addi-
tion, RNA-Seq of  whole blood (WB) cells was performed on 21 HS patients and 10 healthy controls, with 
20 of  the HS patients and all the healthy controls having both skin and WB samples profiled. Principal 
components analyses (PCAs) of  skin showed nearly complete separation between HS and healthy control 
skin (Figure 1A), whereas PBMCs showed less clear separation (Figure 1A). Using a fold change thresh-
old of  2 and false discovery rate (FDR) of  0.1, we detected 4797 differentially expressed genes (DEGs) 
in HS skin compared with control skin, of  which 2584 were increased and 2213 were decreased. Several 
genes were found to be increased simultaneously in both HS skin and HS blood. These included CCR4, 
TNFRSF4, and several genes involved in immunoglobulin biosynthesis (Supplemental Figure 1). The most 
upregulated genes in skin were associated with B cell responses, including immunoglobulin genes such 
as IGLV3-27 (100-fold increased, adjusted P = 2.74 × 10–5), CD19 (33-fold, adjusted P = 6.48 × 10–24), and 
CD79a (32-fold, adjusted P = 3.58 × 10–22). Other genes included the antimicrobial gene DEFB4A (24-fold, 
adjusted P = 2.71 × 10–10); CXCL13, a B cell chemoattractant (16-fold, adjusted P = 1.25 × 10–8); and the 
neutrophil chemokine CXCL1 (2.8-fold, adjusted P = 2.91 × 10–2). In the WB, there were 332 DEGs, of  
which 230 were increased and 102 decreased (Supplemental Tables 2 and 3).
HS shows a complex inflammatory profile distinct from that of  psoriasis or atopic dermatitis and enriched in genes 
involved in B cell function. To address the major transcriptomic characteristics of  HS, we compared it with 
RNA-Seq data from psoriasis (n = 28) and atopic dermatitis (AD) (n = 32) (15) because the inflammatory 
responses in these 2 diseases are well characterized, and many of  the drugs currently approved for these 
diseases are currently being repurposed for treatment of  HS. Interestingly, genes dysregulated in lesional 
skin for all 3 diseases included the antimicrobial genes DEFB4A, SPRR2F, CD177, and TCN1. In terms of  
expression of  proinflammatory cytokine genes in HS, we observed increased mRNA expression of  IFNG 
(2.6-fold, adjusted P = 2.6 × 10–2), IL17A (8.6-fold, adjusted P = 6.7 × 10–7), IL17F (13.3-fold, adjusted P 
= 1.9 × 10–9), IL36A (9-fold, adjusted P = 1.2 × 10–4), and IL36G (2.4-fold, adjusted P = 1.7 × 10–2) com-
pared with healthy controls, whereas IL13 and IL17C expression were overall decreased (Figure 1B and 
Supplemental Figure 2). Notably, the elevation of  IL17A and IL17F expression in HS was comparable to 
the expression levels in psoriatic skin. With regard to the magnitude of  the cytokine response in HS skin, 
we observed significant responses for stimulation of  type II IFN (i.e., IFN-γ; P = 5.9 × 10–5) and IL-36 (P 
= 9.3 × 10–4) in HS lesional skin, whereas the effect of  Th2 response (i.e., IL-4), IL-17A, or TNF stimula-
tion was absent in HS skin (Figure 1C). These data demonstrate lack of  a dominant Th cytokine axis in 
HS, in contrast to AD (Th2) or psoriasis (Th17). To address the unique inflammatory responses in HS, we 
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compared HS with either psoriasis or AD and found that the most prominent genes unique to HS included 
genes encoding immunoglobulins (Figure 1D). Using bulk RNA-Seq data from HS skin, we interrogated 
for cell type–specific signatures. For HS skin the top 3 cell signatures were assigned to B cells (P < 1 × 10–40), 
followed by various T cell populations, including Th2, and CD4+ and CD8+ effector memory cells (P < 1 
× 10–12) (Figure 1E). In contrast, cell type signatures in blood included CD4+ naive cells (P < 1 × 10–20), 
Th17 cells (P < 1 × 10–15), and Th2 cells (P < 1 × 10–12) (Figure 1E). Biological processes enriched among 
increased DEGs in HS skin included immune response (adjusted P = 7.64 × 10–84), regulation of  immune 
response (adjusted P = 8.26 × 10–82), complement activation (adjusted P = 2.09 × 10–56), Fc-gamma receptor 
signaling pathway (FDR = 8.86 × 10–41), innate immune response (FDR = 4.92 × 10–33), B cell receptor sig-
naling (FDR = 2.32 × 10–23), and neutrophil chemotaxis (FDR 8.75 × 10–11). Biological processes enriched 
among decreased DEGs included PPAR signaling pathway (adjusted P = 3.17 × 10–7) and steroid biosyn-
thesis (adjusted P = 0.008). KEGG pathways among decreased DEGs included cholesterol biosynthetic 
process (adjusted P = 9.64 × 10–11) and lipid metabolic process (adjusted P = 5.5 × 10–4) (Figure 1F).
Figure 1. Characterization of the inflam-
matory process in HS by RNA-Seq is 
suggestive of heightened B cell respons-
es. PCA plots of skin (top, red), and 
blood (bottom, blue) in patients with 
HS (n = 22) and healthy controls (n = 10) 
(A). Comparison of fold change mRNA 
expression of key proinflammatory 
cytokines in HS compared with psoriasis 
and AD (n = 22 HS, n = 28 psoriasis, n = 
32 AD). Medians are shown in the middle 
of each plot. (B). Comparison of key 
proinflammatory cytokine responses in 
HS skin compared with psoriasis and AD. 
(n = 22 HS, n = 28 psoriasis, n = 32 AD) 
(red bar indicates baseline responses in 
uninflamed control skin) (C). Comparison 
of DEGs in HS skin against psoriasis (n = 
28) and AD (n = 32). Unique genes in HS 
are shown in red, genes unique to psori-
asis or AD are shown in green, and genes 
significant in both are shown in blue 
(D). Enriched B cell signatures in skin 
of patients with HS but T cell respons-
es in blood of patients with HS (E). 
Enriched biological processes and Kyoto 
Encyclopedia of Genes and Genomes 
(KEGG) pathways in increased (top) and 
decreased (bottom) DEGs in HS skin (F).
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Single-cell RNA-sequencing outlines the cellular composition of  HS. Single-cell RNA-sequencing (scRNA-
Seq) was performed on cells isolated from 9 excisional samples from patients with severe HS. We collected 
30,636 cells with a median 1974 genes and a median 7342 transcripts. We did unsupervised clustering anal-
ysis and grouped the cells into 22 clusters (Figure 2A), which were further annotated as 10 cell types includ-
ing keratinocytes, melanocytes, fibroblasts, smooth muscle cells, endothelial cells, B cells, plasma cells, T 
cells, myeloid cells, and mast cells (Figure 2A). Three representative signature genes for each cell type are 
shown in the heatmap (Figure 2B). To learn cell-cell communication between the cell types, we performed 
CellPhoneDB ligand-receptor analysis and plotted the top ranked 200 pairs in a Circos plot (Figure 2C). 
We also show the connection linked from or to B cells and plasma cells (Figure 3, A and B). The ligand-re-
ceptor analysis demonstrated extensive interactions between all the major cell subsets in HS, including 
interactions of  B cells and plasma cells with stromal tissue cells and other immune cell components. Nota-
ble interactions include members of  the Notch signaling pathway with endothelial and keratinocyte cell 
populations, keratinocyte-derived CCL20 with T cells, and interaction of  IFN-γ with various stromal cell 
clusters (Supplemental Table 4). We identified both IL17A- and IFNG-expressing T cells in HS skin (Supple-
mental Figure 4 and Supplemental Figure 5). Notably, IL18, a promoter of  IFN-γ responses (16), was pri-
marily derived from keratinocytes (17). We also performed enrichment analysis on the signature genes for 
each cell type, demonstrating enrichment of  complement activation (P = 5.0 × 10–11), positive regulation of  
B cell activation (P = 2.8 × 10–10), and antibacterial humoral response (1.6 × 10–5) in the plasma cell popula-
tion; B cell receptor signaling pathway (P = 4.1 × 10–8) and IFN-γ mediated signaling pathway (P = 0.03) in 
B cells; inflammatory response (P = 6.2 × 10–15) and neutrophil chemotaxis (P = 3.9 × 10–7) in the myeloid 
cell population; and T cell receptor signaling pathway (P = 1.8 × 10–14), T cell costimulation (P = 7.0 × 
10–11), and regulation of  TNF-mediated signaling (P = 8.4 × 10–6) in the T cell compartment (Figure 2D).
Keratinocytes show heightened type II IFN and IL-36 responses. To study the cytokine response in the larg-
est population in our scRNA-Seq data, we performed subclustering on the keratinocytes and obtained 13 
subclusters (Figure 4A). The top marker genes for each subcluster are shown in Figure 4B. We used a 
broad range of  cytokine response signatures, as previously described by our group (15), to interrogate each 
keratinocyte subcluster for a particular inflammatory signature (Supplemental Table 5). A module score for 
each cytokine was calculated for each cell based on the expression of  the signature genes induced by the 
cytokine. Then the module scores for each subcluster were plotted in Figure 4C. This demonstrates high 
inflammatory burden in keratinocytes in subcluster 7, particularly for IL-17 responses (adjusted P < 1 × 
10–250), IL-36 responses (adjusted P = 6.4 × 10–77), and TNF responses (adjusted P = 2.7 × 10–9). This cluster 
was characterized by high expression of  antimicrobial genes, such as DEFB4A, S100A7A, and IL36G. In 
contrast, subclusters 0, 1, 2, 3, and 8 showed enrichment for both type I and type II IFN responses (adjusted 
P < 1 × 10–250), with IFN-γ additionally showing an enriched response in subcluster 7 (adjusted P < 1 × 
10–250). The distribution of  each cytokine response can also be observed by plotting the module scores on 
the uniform manifold approximation and projection (UMAP) (Figure 5A). To address the specificity of  
each signal, we focused on the 4 main responses: IFN-γ, TNF, IL-17A, and IL-36. Of  these, unique cyto-
kine responses were most abundant for IFN-γ, followed by IL-36 and TNF (red lines) (Figure 5B), whereas 
nonspecific and overlapping responses were observed for IL-17A and to a lesser extent for the other cyto-
kine responses (gray lines, Figure 5B). These data demonstrate that only a proportion of  keratinocytes are 
responding to inflammatory stimuli in HS and that these responses are dominated by IFN-γ, followed by 
IL-36G and TNF, with lesser contribution by IL-17A.
B cells and plasma cells predominate in HS skin lesions. To determine whether the transcriptomic signatures 
align with the cellular infiltrates in HS, we used CyTOF imaging to identify and quantify infiltrating leu-
kocytes. HS skin had a marked increase in leukocyte infiltration compared with normal skin (Figure 6A). 
When visualized using the dimensional reduction tool t-SNE, there was complete separation between the 
leukocyte clustering in HS skin compared with normal skin, with 12 distinct clusters being observed in HS 
and 2 clusters in normal (Figure 6B). Markers characterizing each cluster are shown (Figure 6, C and D), 
with plasma cells being the predominant infiltrating leukocyte population in HS skin, followed by B cells, 
monocyte/macrophages, CD8+ T cells, and neutrophils (Figure 6E). These results demonstrate that plasma 
cells and B cells constitute the dominant infiltrating leukocyte population in HS. B cell and plasma cell 
subsets and associated gene transcripts are shown in Supplemental Figure 6.
HS skin shows increased immunoglobulin production and diversity accompanied by complement activation. To char-
acterize the HS immune repertoire, B cell receptor (BCR) and TCR gene segments and complementarity 
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Figure 2. scRNA-Seq helps 
characterize the inflamma-
tory cell composition of HS. 
scRNA-sequencing (scRNA-
Seq) was performed on skin 
cells isolated from patients 
with moderate-to-severe HS 
undergoing surgical excisions 
(n = 9). Information on 30,636 
cells across 23 cellular clusters 
representing 10 cellular subsets 
(A). Heatmap of the top 3 tran-
scripts in each cluster showed 
clear demarcation between 
different clusters (B). Cell-cell 
receptor-ligand communication 
between inflammatory infiltrate 
and stromal tissues for the top 
200 receptor-ligand pairs (C). 
Enriched biological categories 
among genes expressed in the 4 
major inflammatory cell clusters (D).
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determining region 3–encoding (CDR3-encoding) sequences were mined from RNA-Seq data sets obtained 
from skin and blood of  HS patients and healthy controls. This analysis revealed that based upon BCR CDR3 
sequences and BCR gene segment abundances, there was a significant increase in the frequency of  B cells in 
HS skin (P = 7.8 × 10–5, 6.7 × 10–5, 9.8 × 10–5 and P = 8.3 × 10–5, 7.9 × 10–5, 1.4 × 10–4 for BCR IgH, κ, λ clones 
per million and BCR IgH, κ, λ gene segment reads per million, respectively) (Figure 7A). Next, to evaluate if  
there were any qualitative changes in the repertoire, BCR CDR3 alpha diversity was assessed by calculating 
the Shannon index (Figure 7A). This analysis revealed that the HS BCR repertoire was significantly more 
diverse than that of  control skin (P = 5.8 × 10–5, 1.6 × 10–4, and 1.4 × 10–6 BCR IgH, κ, λ clone Shannon 
diversity, respectively). To further evaluate whether the cutaneous B cell repertoire was qualitatively altered 
in the setting of  HS, Jaccard distances were calculated as a measure of  dissimilarity. Principal coordinates 
analysis (PCoA) plots of  the beta diversity measures indicated good segregation of  samples by disease status 
for BCR κ and λ light chain (Figure 7B). There was no separation by disease status when this analysis was 
performed for IgH CDR3 sequences. Thus, at least at the level of  the BCR light chain gene rearrangements, 
Figure 3. Interactions of B cells and plasma cells with HS microenvironment. Data from single-cell sequencing were used to map receptor-ligand interac-
tions from and to B cells (A) and to and from plasma cells (B) (n = 9).
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there were clear qualitative and quantitative differences in the B cell repertoire of  patients with HS. To explore 
this finding further at the level of  individual B cell clones, heatmaps were constructed from data on clone fre-
quencies across HS and healthy control skin. Similar to the PCoA plots, the frequencies of  clonal abundance 
at the level of  BCR κ and λ CDR3s across subjects was different enough to separate HS from healthy controls 
(Figure 7C). To assess deposition of  IgGs and complement activation in HS, we stained for components and 
breakdown products of  the complement pathway. This showed prominent protein expression of  C1q, C3b, 
and C4d in HS skin, particularly in the deeper layers of  the skin (Figure 7D). Complement receptors CR1 and 
CR2 were also increased in HS skin, along with IgG immune complex deposition (Figure 7E). To determine 
if  this contributed to the proinflammatory environment in HS, we costained for TNF, the best characterized 
inflammatory mediator in HS, against B cells (CD20) and plasma cells (CD138). This showed nearly exclu-
sive colocalization of  TNF to plasma cells (Figure 7F). Less pronounced shifts in the mRNA expression of  
TCRs (TRA, TRB, TRD, TRG) was seen, in terms of  both total reads and diversity (Supplemental Figure 3).
BCR and Bruton’s tyrosine kinase signaling are potential therapeutic targets in HS. To validate our transcriptomic 
findings, we performed IHC of excisional HS tissue of longstanding duration and with prominent sinus forma-
tion. This showed positive staining for CD3+ T cells, CD20+ B cells, and CD138+ plasma cells mostly concen-
trated in the deeper aspect of the biopsy, around a sinus tract (Figure 8A). Analysis of the signal transduction 
network using literature-based networks (GePS) demonstrated enrichment for BCR signaling (P < 1 × 10–25), 
Figure 4. Inflammatory responses in HS keratinocytes have elevated type II IL-17, TNF, and IL-36 responses. Transcriptomic information was available 
on 20,587 keratinocytes from HS skin. These were divided into 13 clusters (A). A dot plot showing the top 3 markers for each cluster marked the defining 
genes for each cluster, although with some overlap between clusters (B). Transcriptomic cytokine responses from several proinflammatory cytokines were 
used to interrogate each keratinocyte for each particular inflammatory signature, with cluster 7 showing overall the highest and broadest inflammatory 
signal, but with different specific inflammatory responses having different cluster localization in HS keratinocytes (n = 9) (see Methods) (C).
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spleen tyrosine kinase (SYK) signaling (P < 1 × 10–22), and Bruton’s tyrosine kinase (BTK) signaling (P < 1 × 
10–13), with enriched signals for IL-17A (P < 1 × 10–7), granzyme B (P < 1 × 10–7), and CCR5 (P < 1 × 10–4) (Fig-
ure 8B). Activation of these signaling pathways was validated by IHC for phospho-BTK and phospho-SYK 
(Figure 8C). Network analysis showed prominent clustering of increased HS DEGs around BTK and SYK 
nodes (Figure 9A). To determine therapeutic potential of these targets in HS, we used IgG/IgM-stimulated 
B cells, treated with the BTK inhibitors acalabrutinib and ibrutinib, or the SYK inhibitor fostamatinib, and 
determined transcriptomic overlap and responses against DEGs in HS skin. The monocyte chemokine CCL4 
was one of the most highly expressed chemokines in HS skin, with its mRNA expression increased by 7.7-fold 
(FDR = 4.1 × 10–3). Its expression was suppressed 19-fold by acalabrutinib, adjusted P = 5.6 × 10–5, and 22.8-
fold by ibrutinib, adjusted P = 2.2 × 10–3 (Supplemental Table 6). Less pronounced overlap was seen for the 
SYK inhibitor fostamatinib (Figure 9B).
Discussion
The etiology of  HS is still incompletely understood but appears to be complex, with multiple factors con-
tributing to its pathogenesis, including obesity, sex, hormonal factors (5), dysregulated microbiota (18, 19), 
and genetics (6). In contrast to many other chronic inflammatory diseases, no genome-wide association 
studies have been performed in HS. However, studies on autosomal dominant forms of  HS have identified 
mutations in genes belonging to the gamma-secretase complex, involved in regulation of  Notch signaling 
activity (6), although in sporadic HS, these mutations seem to represent only a small minority of  HS cases 
(7). One of  the hallmark features of  HS is the presence of  deeply invasive epithelial tendrils that form tracts 
and keratin-filled cysts. Notably, in mouse skin, in the absence of  gamma-secretase function, there is con-
version of  hair follicles to epidermal cysts with irregular ingrowths (20), suggesting that abnormal activity 
of  gamma-secretases, and Notch signaling, may drive this feature of  HS, although in this model no inflam-
mation was noted (20). Whether the inflammatory response in HS is driving the ingrowth of  epithelial 
Figure 5. IFN-γ and IL-36 responses are the most prominent keratinocyte immune responses in HS skin. Specific cytokine responses were superimposed 
on the keratinocyte UMAP clusters to determine the distribution of key cytokine responses across different clusters (A). Circos plots were used to show 
the connection between the major inflammatory signals (lines) and the specificity (red line) to different keratinocyte clusters (clusters 0–12). Of these the 
IFN-γ and IL-36 responses had the highest degree of specificity (B) (n = 9).
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tendrils or, conversely, tendril growth followed by rupture and release of  keratinized and bacterial contents 
from the cysts and tracts is responsible for the inflammation is still unknown. While none of  the NOTCH, 
NOTCH ligands, or gamma-secretase genes (NCSTN, PSENEN, and PSEN1) were differentially expressed 
in our data set, it is possible that our data did not capture changes in gamma-secretase or Notch signaling, 
as our study was focused on patients with chronic, established inflammatory disease. However, the early 
sequence of  events in HS will need to be addressed in future studies.
Several studies have implicated complement activation in the pathogenesis of  HS. This includes studies 
showing elevated C5a (8), which is a breakdown product of  complement pathway activation and a major 
Figure 6. B and plasma cells are the dominant infiltrating leukocytes in HS. Analysis of the CyTOF data by t-distributed stochastic neighbor embedding 
(t-SNE) dimensionality reduction demonstrated clear separation between HS and normal skin (A) (scale bar: 100 μm), with the staining forming 14 distinct 
Phenograph clusters, of which only 2 were found in normal skin (B and C). Heatmap showing marker expression of each cluster (D). Quantification of the 
different subsets based on surface markers (E) (n = 3, Student’s t test, **P < 0.01; *P < 0.05; NS, nonsignificant).
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neutrophil chemoattractant, in both blood and skin of  HS patients (8). Neutrophils are prominent in HS 
(9), and a recent study demonstrated increased levels of  neutrophils undergoing NETosis in both blood 
and skin of  HS patients, with the amount of  NETs disgorged in HS skin correlating with disease severity 
(10). Furthermore, this same study identified increased levels of  autoantibodies recognizing citrullinated 
peptides and NET antigens (10). A recently published clinical trial using an IgG5 monoclonal antibody that 
selectively binds to C5a and blocks its biological activity demonstrated modest clinical efficacy in HS (21).
Transcriptomic profiling of  HS skin has been performed by several groups, although these studies have 
been limited to relatively low-resolution microarray-based studies (11, 13, 22). These studies have shown 
increased number of  infiltrating CD4+ T cells secreting IL-17 and IFN-γ and increased mRNA expression of  
IL17A and IFNG in HS skin, accompanied by increased IL-17A CD4+ T cells in HS blood, but unchanged 
Figure 7. Increased immunoglobulin production and antibody diversity in HS skin and complement activation. Box-and-whisker plots of BCR CDR3 
expressions (A). The y axis shows normalized log-transformed BCR CDR3 expression. The x axis represents patient group. In all cases there were more 
BCR CDR3 sequences detected in HS skin compared with control healthy skin. Box-and-whisker plots of BCR gene segment expression. The y axis 
shows normalized log-transformed BCR gene segment expression. The x axis represents patient group. The Shannon diversity index for BCR CDR3 
gene segment is plotted on the y axis. The x axis represents patient group. HS skin had a significantly more diverse BCR repertoire (B). Beta diversi-
ty–based principal coordinates analysis (PCoA) of BCR CDR3 sequences. Sample matrix was generated using Jaccard dissimilarities, and respective 
profiles were compared by PCoA. Each color represents 1 patient group, HS (red) and control (blue). This analysis revealed clear separation for κ and λ 
light chains but not Ig heavy chain (C) Hierarchical clustering of expressed TCR V/J gene segment expression. Heatmaps by clonal abundance across 
sample sets. Note good separation of HS from controls based upon clonal abundances in BCR κ and λ repertoires. Components of the complement 
pathway (C1q) and breakdown products of activated complement components (C3b, C4d) were increased in HS skin, particularly in the deeper layers 
of the skin (n = 3) (scale bar: 100 μm) (D). Complement receptors, CR1 and CR2, were increased in the deeper layers of HS, along with IgG1 immune 
complex deposition (n = 3) (scale bar: 100 μm) (E). Immunofluorescence of B cells (CD20) and plasma cells (CD138) showed primary localization of TNF 
to the plasma cell population in HS skin (n = 3) (scale bar: 50 μm) (F). For A and B, the bold vertical line represents the median, and the upper and 
lower limits of the box represent the interquartile range (IQR). The whiskers represent 1.5× IQR.
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frequency of  IFN-γ–secreting cells (11). These studies have suggested IL-17–centric pathogenesis, support-
ed by the role of  IL-17A in psoriasis as one of  the most highly enriched biological processes in HS skin, 
followed by interferon signaling (11), and are consistent with findings from our own group that showed 
increased protein levels of  IL-17A and to a lesser extent IFN-γ in lesional HS skin (12). Furthermore, kera-
tinocyte-derived IL-6 and IL-1β have been implicated in HS pathogenesis (11). Our data did not detect 
increased mRNA expression of  IL1B in HS skin, and IL6 was decreased by about 4-fold (adjusted P = 2.2 
× 10–3) (Supplemental Table 2). Instead, we found evidence for increased expression of  IL36A and IL36G 
(Figure 1). In this context, case reports targeting the IL-1 axis in HS have provided mixed results, with some 
showing modest improvement (23, 24) and others showing no improvement (25). No clinical trial data exist 
on the use of  anti–IL-6 agents in HS, but one study noted development of  HS in a patient undergoing the 
anti–IL-6 treatment tocilizumab (26).
Other inflammatory mediators implicated in HS include the type I IFNs, based primarily on the 
expression of  IFN response genes, such as MX1, CXCL10, and IFI27. The expression of  these was pro-
posed to be driven by NETs interacting with infiltrating pDCs in lesional HS skin (10). In agreement with 
this study, we found evidence for both type I and type II IFN responses in our data set, most prominently 
in 4 of  the scRNA-Seq keratinocyte clusters, which notably did not overlap with other clusters having pro-
nounced IL-17 and TNF responses (Figure 4 and Figure 5). Of  note, we were unable to detect pDCs in the 
scRNA-Seq data, and there was no increase in the mRNA expression of  any of  the type I IFN genes or the 
pDC markers CD123 or CD303. In contrast, mRNA expression of  IFNG was increased by about 2.6-fold, 
and CXCL10 increased by about 2.7-fold, suggesting that IFN-γ might have a greater contribution to the 
IFN response in HS than the type I IFNs.
Figure 8. Enrichment and activation of B cell–associated signaling pathways in HS skin. Analysis of the signal transduction networks using litera-
ture-based networks (Genomatix-Pathway System, GePS) demonstrated enrichment for pathways involved in B cell signaling and activation (A). To 
confirm the nature of the inflammatory infiltrate in HS and the localization of components of the enriched signaling pathways, we performed IHC in an 
excisional biopsy for CD3, CD20, and CD138. Plasma cells were the predominant inflammatory infiltrate and most prominent in the deeper layers of the 
skin surrounding a deeper sinus tract (A), accompanied by increased expression of BTK, SYK, and LCK (B) (n = 3). Activation of key components of this 
signaling pathway was confirmed by IHC for both phospho-BTK and phospho-SYK (n = 3) (C).
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Our data identified B cells, and in particular plasma cells, as a potential therapeutic target in HS. Strikingly, 
TNF expression, the target of the only approved biologic treatment in HS (27), was localized to CD138+ plasma 
cells (Figure 7G). Successful use of B cell targeting in HS has been reported with the anti-CD20 agent rituximab 
in a patient undergoing treatment for an unrelated immune disorder (28). An ex vivo explant study of 10 patients 
in which skin explants were treated with rituximab demonstrated significant decrease in secretion of several 
proinflammatory mediators (12). However, anti-CD20 treatment would be unlikely to target plasma cells, as 
CD20 is downregulated in plasma cells with CD20 detected only on a small minority of plasma cells (29). An 
alternative approach to target plasma cells is to block active signaling pathways in these cells. The most enriched 
Figure 9. B cell receptor signaling is central to HS transcriptomic changes and a potential therapeutic target in HS. Outline of the GePS network in HS 
skin centered on critical inflammatory nodes, including BTK, SYK, JUN, and STAT1 signaling (red/brown indicating increased expression and green indicat-
ing decreased expression) (A). Overlap between gene expression in activated B cells (IgG/IgM stimulated) treated with the BTK inhibitors acalabrutinib and 
ibrutinib and the SYK inhibitor fostamatinib (B) (n = 3).
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pathways in HS involved B cell signaling, including BCR signaling, SYK, LCK, and BTK (Figure 8A), and these 
pathways correlated with B cell (CD3) and plasma cell (CD138) infiltration in HS skin but not T cell (CD3) 
(Figure 8B). Notably, drugs targeting BTK have been shown to prevent plasma cell generation (30), and SYK 
has been shown to play a critical role for B cell antibody responses, memory B cell survival (31), and plasma 
cell expansion (32). While our therapeutic data were limited to B cells, they showed decreased B cell expression 
of several proinflammatory mediators that overlapped with HS skin, including CCL4, and this was more pro-
nounced with the BTK inhibitors acalabrutinib and ibrutinib than the SYK inhibitor fostamatinib (Figure 9B). 
Consistent with an active role of B cells in HS pathogenesis is the observation that these cells are prominent in 
early HS lesions and are the major immune cell population attenuated with anti-TNF treatment (33).
In summary, while our data have some limitations, including analysis of  mostly one ethnicity and lack 
of  perilesional and matched unaffected skin from patients, we provide a comprehensive overview of  the 
inflammatory pathogenesis of  HS and help tie together previously discordant data. As there are no animal 
models of  this disease, our data, through identification of  potentially novel therapeutic signaling pathways, 
provide preclinical evidence that should accelerate the path toward clinical trials targeting either BTK or 
SYK in chronic, moderate-to-severe HS.
Methods
Single-cell RNA-sequencing. Generation of single-cell suspensions for scRNA-Seq was performed as follows: 
lesional HS tissue was obtained from excisional samples from patients with severe HS. Samples were incubated 
overnight in 0.4% dispase (Life Technologies, Thermo Fisher Scientific) in Hank’s Balanced Saline Solution 
(Gibco, Thermo Fisher Scientific) at 4°C. Epidermis and dermis were separated. Epidermis was digested in 
0.25% Trypsin-EDTA (Gibco, Thermo Fisher Scientific) with 10 U/mL DNase I (Thermo Fisher Scientific) 
for 1 hour at 37°C, quenched with FBS (Atlanta Biologicals), and strained through a 70 μM mesh. Dermis was 
minced, digested in 0.2% Collagenase II (Life Technologies, Thermo Fisher Scientific) and 0.2% Collagenase 
V (MilliporeSigma) in plain medium for 1.5 hours at 37°C, and strained through a 70 μM mesh. Epidermal 
and dermal cells were recombined, and libraries were constructed by the University of Michigan Advanced 
Genomics Core on the 10x Genomics Chromium system. Libraries were then sequenced on the Illumina 
NovaSeq 6000 sequencer to generate 151 bp paired-end reads. Data processing, including quality control, read 
alignment, and gene quantification, was conducted using the 10x Genomics Cell Ranger software. Seurat was 
used for normalization, data integration, and clustering analysis (34). Clustered cells were mapped to corre-
sponding cell types by matching cell cluster gene signatures with putative cell type–specific markers.
RNA-sequencing. Skin biopsies of  4 mm in diameter were taken, placed in tubes with RNAlater (Invi-
trogen, Thermo Fisher Scientific), stored overnight at 4°C, and subsequently stored at –80°C until fur-
ther processing. RNA isolation and sequencing were performed using the Illumina NextSeq platform and 
sequencing protocols as previously described (35). For RNA-Seq analyses, adapter trimming and quality 
control were conducted on the raw sequence reads. The paired-end reads were mapped using STAR (36) to 
human build GRCh37, and only uniquely mapped reads were used for subsequent analysis. RNA-Seq data 
from psoriasis and AD were obtained (37). Gene expression levels were quantified (GENCODE v24 was 
used as reference) and normalized by HTSeq (38) and DESeq2 (39), respectively. Negative binomial model 
in DESeq2 were used to conduct differential expression analysis.
TCR/BCR analyses. MiXCR software was used to extract TCR and BCR CDR3 sequences from RNA-
Seq data. Analysis was performed with the “-p rna-seq” option recommended for analysis of  RNA-Seq 
data (40, 41). Data visualization and TCR repertoire comparison were performed in R (42, 43). The CDR3 
region was defined according to the International ImMunoGeneTics (IMGT) nomenclature. Likewise, 
gene names of  V and J regions were defined according to the IMGT name nomenclature for TCRs of  mice 
as previously described (44, 45). Clone abundances across samples were plotted using the “pheatmap” R 
package (https://cran.r-project.org/web/packages/pheatmap/index.html). The heatmap was constructed 
using Euclidean distance with complete linkage on centered data using the top clones showing greatest 
variance. Alpha diversity was assessed by calculating the Shannon diversity index using the vegan software 
package in R (https://cran.r-project.org/web/packages/vegan/index.html). The Shannon diversity index 
quantifies diversity through the incorporation of  both evenness and richness, with higher values represent-
ing more even populations of  TCR- or BCR-rich samples. The differences in beta diversity were assessed 
based on Jaccard distances calculated using the vegan software package in R. To visualize the Jaccard dis-
similarities between the samples, PCoA using R package ape was performed.
1 4insight.jci.org   https://doi.org/10.1172/jci.insight.139930
R E S E A R C H  A R T I C L E
CyTOF imaging. Formalin-fixed, paraffin-embedded tissue slides obtained from HS patients and healthy 
controls were heated for 2 hours at 60°C, deparaffinized, and rehydrated. Slides were placed in pH 9 Tris/
EDTA antigen retrieval buffer and heated at 96°C for 30 minutes. After cooling, slides were blocked in 3% BSA 
and stained with a cocktail of  metal-tagged antibodies overnight at 4°C, including CD14 (EPR3653, Abcam), 
CD16 (EPR16784, Abcam), CD68 (KP1, BioLegend), CD15 (W6D3, Fluidigm), CD31 (JC/70A, Novus), 
CD45 (2B11, Novus), E-Cadherin (24E10, Fluidigm), CD20 (L26, Novus), CD8 (C8/144B, Fluidigm), col-
lagen (polyclonal, Fluidigm), CD27 (EPR8569, Abcam), CD103 [EPR4166(2), Abcam], CD138 (MI15, Bio-
Legend), and pan-actin (D18C11, Cell Signaling Technology). The slides were then washed with 0.2% Triton 
X-100 and stained with Intercalator-Ir (Fluidigm) for 30 minutes at room temperature in a hydration chamber. 
The stained tissue was ablated and raw data were acquired on the Hyperion Imaging System (Fluidigm).
CyTOF imaging data analysis. Multiplexed CyTOF imaging data were preprocessed using commer-
cial acquisition software (Fluidigm) and converted to.TIFF images. These images were then segmented 
into individual cells using CellProfiler v3.1.8 for single-cell analysis. The t-SNE dimensionality reduction 
algorithm and the Phenograph unsupervised clustering algorithm were performed on 12 markers (CD20, 
CD15, CD27, CD68, CD16, CD14, CD138, CD31, CD103, CD45, CD3, and CD8) using HistoCAT 
v1.75 software. For t-SNE and Phenograph, the data were normalized to the 99th percentile. The heatmap 
shows Z-scored mean marker expression of  each cluster. P values were computed using 2-tailed Student’s t 
tests assuming homoscedasticity.
Immunohistochemistry. Paraffin-embedded tissue sections from excisional biopsies from patients with hidra-
denitis and healthy control skin were heated at 60°C for 30 minutes, deparaffinized, and rehydrated. Slides 
were placed in pH 6 antigen retrieval buffer and heated at 125°C for 30 seconds in a pressure cooker water bath. 
After cooling, slides were treated with 3% H2O2 (5 minutes) and blocked using 10% goat serum (30 minutes). 
Overnight incubation (4°C) was performed using CR1 (CD35) (LifeSpan Biosciences, catalog LS-C675585, 
5 μg/mL) and CR2 (CD21) (LifeSpan Biosciences, catalog LS-C167018, concentration 1:50). Staining done 
in antigen retrieval buffer at pH 9 included IgG1 (Abcam, catalog ab233885, 5 μg/mL), phospho-SYK (Cell 
Signaling Technology, catalog C87C1, 1:100), phospho-BTK (Invitrogen, Thermo Fisher Scientific, catalog 
14-9015-82, 1:100), CD3 (Abcam, catalog ab17143, 1:10), C1q (LifeSpan Biosciences, catalog LS-B14993-100, 
2 μg/mL), C3b (Abcam, catalog ab200999, 2 μg/mL), C4d (LifeSpan Biosciences, catalog LS-B3921-125, 2 
μg/mL), LCK (LifeSpan Biosciences, catalog LS-B2049-50, 5 μg/mL), BTK (Sino Biological, catalog 10578-
T44-50, 1 μg/mL), and SYK (Abcam, catalog ab40781, 1 μg/mL). Slides were then washed and treated with 
appropriate secondary antibodies, peroxidase (30 minutes), and diaminobenzidine substrate.
Immunofluorescence. Formalin-fixed, paraffin-embedded tissue slides obtained from patients and healthy 
controls were heated for 30 minutes at 60°C, deparaffinized, and rehydrated. Slides were placed in pH 9 
antigen retrieval buffer and heated at 125°C for 30 seconds in a pressure cooker water bath. After cooling, 
slides were blocked using 10% donkey serum (30 minutes). Overnight coincubation (4°C) was then per-
formed using anti–human TNF (Abcam, catalog ab6671), anti–human CD20 (Santa Cruz Biotechnology, 
catalog sc-393894), and anti–human CD138 (LifeSpan Biosciences, LS-B9360-50). Slides were then washed 
and treated with relative fluorescence-conjugated secondary antibodies (30 minutes). The secondary anti-
body used with anti–human TNF was Alexa Fluor 488 AffiniPure donkey anti–rabbit IgG (Jackson Immu-
noResearch Laboratories, catalog 711-545-152). The secondary antibody used with anti–human CD20 
and anti–human CD138 was Alexa Fluor 594 AffiniPure donkey anti-mouse IgG (Jackson ImmunoRe-
search Laboratories, catalog 715-585-151). Slides were prepared in mounting medium with 4′,6-diamid-
ino-2-phenylindole (DAPI) (VECTASHIELD Antifade Mounting Medium with DAPI, H-1200, Vector 
Laboratories, Maravai LifeSciences). Images were acquired using a ZEISS Axioskop 2 microscope. Images 
presented are representative of  at least 3 biologic replicates.
B cell stimulations and inhibitor experiments. Fostamatinib disodium, ibrutinib, and acalabrutinib in 
DMSO were purchased from Selleck Chemicals LLC. Lymphoprep (STEMCELL Technologies) was used 
to isolate the buffy coat from healthy donor volunteer blood, and the EasySep Human B Cell Isolation Kit 
(STEMCELL Technologies) was used to isolate B cells. Cells were incubated overnight at 37°C. Stimula-
tion was performed with 5 μg/mL each of  Goat F(ab′)2 Anti-Human IgM and Goat F(ab′)2 Anti-Human 
IgG (SouthernBiotech, catalog 2022-01 and 2042-01) in the presence of  fostamatinib disodium (1 μM), 
ibrutinib (0.4 μM), acalabrutinib (1 μM), or DMSO control for 6 hours at 37°C. Viability assessed by try-
pan blue exclusion exceeded 90% for all conditions. Cells were washed in cold PBS, and RNA was isolated 
using the RNeasy Mini Kit (QIAGEN). Stranded mRNA libraries were prepared using the NEBNext Ultra 
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II RNA Library Prep with poly(A) (New England Biolabs) and sequenced on the Illumina NovaSeq 6000 
sequencer by the University of  Michigan Advanced Genomics Core. Data were analyzed using the Scien-
tific Data Analysis Platform (SciDAP) (Datirium) (46): Trim Galore RNA-Seq pipeline paired-end strand 
specific was used to trim adapters, map reads to GRCh38 (hg38), and quantify gene expression. DESeq (39) 
was used to perform differential expression analysis. Additional details on SciDAP pipelines are available 
at https://scidap.com/public/workflows.
Data availability. Transcriptomic data sets can be accessed at the National Center for Biotechnology 
Information’s Gene Expression Omnibus database (GSE154775 and GSE154773).
Statistics. PCA was conducted using inverse-normalized expression levels of  all detectable transcripts. 
FDR ≤ 10% and |log2 fold change| ≥ 1 were used to declare significance in differential expression anal-
ysis. Significantly regulated genes were analyzed by creating biological literature-based networks using 
software (GePS, version v3. 110621) (https://www.genomatix.de). The function-word level was used as 
the minimum evidence level parameter. We ran CellPhoneDB using all the cell types with the default 
parameters (47). For all single-group comparisons, if  data passed normality test, we used 2-tailed Stu-
dent’s t test. Otherwise data were analyzed using the Mann-Whitney U test. All data are representative 
of  at least 2 independent experiments as detailed in the figure legends. A P value of  less than or equal to 
0.05 was considered significant. For all data related to the RNA-Seq analyses, a threshold of  FDR ≤ 0.1 
was used for significance.
Study approval. Twenty-two patients with moderate-to-severe HS undergoing surgery were recruit-
ed from the specialized HS outpatient clinic of  the Department of  Dermatology, Erasmus University 
Medical Center (Erasmus MC), Rotterdam, the Netherlands. Patients were off  any topical or systemic 
treatment at least 2 weeks before enrollment. Biopsies from lesional skin and blood samples were 
collected during routine HS surgery. Ten healthy controls were recruited from patients undergoing 
surgery for skin cancer or abdominoplasty. All samples were obtained with written informed consent 
from the participants in accordance with Declaration of  Helsinki principles. The study protocol was 
approved by the Institutional Review Board of  the Erasmus MC (MEC-2013-337). The patient charac-
teristics are listed in Supplemental Table 1.
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